Single-use medical devices

“It accounted for 60% of total revenue, with organic revenue growth of 15.4%.”

Annual report 2025A · The company itself

“GLOBAL ENDOSCOPY MARKET A market opportunity of DKK 190bn Global single-use endoscopy market opportunity The market potential of single-use endoscopy represents a DKK 190bn opportunity at full single-use penetration. Across the four major endoscopy areas – Respiratory, Urology, Ear- Nose-Throat, and Gastroenterology – only 3-4% of that potential has been realized, reflecting a significant headroom for further growth.”

Annual report 2025A · The company itself

“As the market leader in single-use endoscopy, Ambu is heading up this structural shift. We offer the broadest single-use solutions portfolio and a proprietary technology platform, EndoIntelligence™, designed to help clinicians and health systems treat more patients and drive better outcomes.”

Annual report 2025A · The company itself

“S Respiratory (formerly named Pulmonology) and Urology are Ambu’s core business areas. In both, our strategic choice is to ‘win’ – by expanding our leadership position and driving the transition toward making singleuse the standard of care.”

Annual report 2025A · The company itself

“As the global shift toward single-use endoscopy gains momentum, we continue to lead the way, powered by strong performance in our Endoscopy Solutions portfolio and our clear commitment to helping hospitals and clinicians achieve higher efficiency, better economics, and clinically impactful care.”

Annual report 2025A · The company itself

“As the global leader in single-use endoscopy, we recognize our responsibility to lead the transition toward more sustainable healthcare.”

Annual report 2025A · The company itself

“For example, we rely on a single source for the SureClick autoinjectors used in the drug delivery of a number of our products, including Repatha and ENBREL.”

Annual report 2025A · The company itself

“Many of our products and product candidates may be used in combination with a drug delivery device, such as an injector or other delivery system. For example, Neulasta is available as part of the Neulasta Onpro kit, our AutoTouch reusable autoinjector is used with ENBREL Mini single-dose prefilled cartridges, Repatha can be administered with the Repatha SureClick autoinjector, and WEZLANA uses our ConfiPen drug delivery device. In addition, some of our products or product candidates, including many of our oncology product candidates and products, including LUMAKRAS/LUMYKRAS, may also require the use of a companion or other diagnostic device such as a device that determines whether the patient is eligible to use our drug or that helps ensure its safe and effective use.”

Annual report 2025A · The company itself

“This increased regulation could require us or our third-party sterilization service providers to temporarily suspend operations to install additional emissions control technology, limit the use of ethylene oxide or take other actions, which would impact our operations and further reduce the available capacity to sterilize medical devices and healthcare products, and could also result in additional costs. If any existing regulatory requirements or any such regulatory actions or rulemaking result in the suspension or interruption of our sterilization operations or at third-party medical device sterilizers we use, or otherwise limit the availability of third-party sterilization capacity, which could interrupt or otherwise adversely impact production of certain of our products or lead to civil litigation or other claims against us.”

Annual report 2025A · The company itself

“On January 14, 2025, the EPA published the Pesticide Registration Review; Interim Registration Review Decision for Ethylene Oxide (“ID”), which regulates the use of ethylene oxide as a sterilant and is intended to mitigate any human health and environmental risks associated with its use. Among other things, the ID requires medical device sterilization facilities to comply with a new and stricter occupational ethylene oxide exposure limit, establish engineering controls for worker protection, provide workers with personal protective equipment, conduct continuous stationary indoor monitoring and comply with a maximum concentration limit for ethylene oxide (with higher levels permitted if required and approved by the FDA).”

Annual report 2025A · The company itself

“We are in the process of assessing the impact of the ID requirements on our sterilization facilities, the third-party sterilization facilities that we utilize and our operations generally. We expect to implement certain changes at our facilities to comply with NESHAP and ID requirements, which will require us to incur additional implementation and ongoing operating costs.”

Annual report 2025A · The company itself

“One of the world’s largest manufacturers of spunmelt nonwovens for the personal care industry. Mainly sells products for baby diapers, femcare and incontinence products.”

Annual report 2025A · The company itself

“Our success also depends on our ability to maintain and routinely improve product quality and our quality management program. Quality management plays an essential role in helping to meet customer requirements, prevent defects, improve our products and services, and assure the safety and efficacy of our products.”

Annual report 2025A · The company itself

“Additionally, our resource outflow of single-use products and waste generated from operations also contributes to environmental impacts.”

Annual report 2025A · The company itself

“Recyclable content in products and packaging: Products after use are considered non-recyclable because of the use phase and contamination with bodily fluids.”

Annual report 2025A · The company itself

“Coloplast’s business areas are single-use products, where the concept of durability and reparability is different from traditional long-lasting products. Single-use products are designed for one-time or short-term use and are typically discarded after fulfilling their purpose.”

Annual report 2025A · The company itself

“En leverantör av engångsprodukter och lösningar för sårbehandling, förbättring av operationssäkerhet och -effektivitet, samt förebyggande av trycksår. www.molnlycke.com • Som en ledande leverantör av innovativa, evidensbaserade kvalitetsprodukter inom sårvård, förebyggande av trycksår och operation erbjuder Mölnlycke attraktiva möjligheter till långsiktig, lönsam organisk tillväxt. • Det är högt prioriterat för Mölnlycke attdriva långsiktig tillväxt genom investeringar i innovation, inklusive digitala initiativ, samt i kommersiell exekvering och hållbarhet.”

Annual report 2022A · The company itself

“As a developer and manufacturer of nonwovens used largely in single-use applications, we operate in a value chain where raw material choices, manufacturing efficiency and product end-of-life all shape our impact.”

Annual report 2025A · The company itself

“Suominen’s nonwovens create value for our customers and end-users by offering safe and high-quality wiping, medical and hygiene products and diverse sustainable alternatives, including biodegradable, compostable and plastic-free products and products manufactured using recycled materials.”

Annual report 2025A · The company itself

“The nonwovens produced by Suominen are further processed into single-use products, such as wipes.”

Annual report 2025A · The company itself

“Suominen’s nonwovens are, for the most part, used in daily consumer goods such as wet wipes as well as in hygiene and medical products.”

Annual report 2025A · The company itself